External validation of cut-off points for foveal thickness taking into account the intraretinal fluid using optical coherence tomography to diagnose diabetic macular oedema [PDF]
PeerJ, 2017 Background In late 2015, cut-off points were published for foveal thickness to diagnose diabetic macular oedema taking into account the presence of intraretinal fluid using optical coherence tomography (OCT) in primary care patients (90 µm in the ...
Carmen Hernández-Martínez +6 more
doaj +2 more sources
Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema
Cells, 2021 Diabetic macular oedema (DMO) is one of the leading causes of vision loss associated with diabetic retinopathy (DR). New insights in managing this condition have changed the paradigm in its treatment, with intravitreal injections of antivascular ...
Milagros Mateos-Olivares +7 more
doaj +1 more source
Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema [PDF]
Farmacia Hospitalaria, 2018 : Objective: To assess the economic impact following the inclusion of an intravitreal implant of dexamethasone for the treatment of diabetic macular oedema in a healthcare area in Spain.
Fernando de Andrés-Nogales +5 more
doaj +1 more source
Intravitreal triamcinolone for diffuse diabetic macular oedema [PDF]
Eye, 2005 To evaluate the efficacy of intravitreal triamcinolone (IVTA) for the treatment of diffuse diabetic macular oedema (DME) refractory to conventional argon macular laser therapy.A prospective, consecutive, and noncomparative case series was undertaken involving 38 eyes of 38 patients with refractory DME.
S K, Gibran +3 more
openaire +2 more sources
Health Technology Assessment, 2022 Background: The National Institute for Health and Care Excellence recommends macular laser to treat diabetic macular oedema with a central retinal subfield thickness of 400 µm.
Noemi Lois +26 more
doaj +1 more source
BMC Ophthalmology, 2011 Background Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduces the risk of visual loss. However recurrences are common and despite laser treatment, patients with diabetic macular oedema experienced progressive loss ...
Norlaili Mustapha +2 more
doaj +1 more source
Accidental intralenticular dexamethasone intravitreal implant with the resolution of macular oedema in central retinal vein occlusion [PDF]
, 2016 No abstract ...
Abdolrahimzadeh, Solmaz +3 more
core +1 more source
Vitrectomy for diabetic macular oedema [PDF]
Eye, 2008 To briefly review and discuss the literature on vitrectomy for diabetic macular oedema.Literature review.There is a copious literature on the subject of vitrectomy for diabetic macular oedema (DMO). The most commonly hypothesised mechanism for the potential benefit of vitrectomy is relief of vitreomacular traction; however, both transvitreal ...
openaire +2 more sources
Multiple myeloma masquerading as diabetic macular oedema [PDF]
BMJ Case Reports, 2018 A 58-year-old man, a known diabetic and hypertensive for 5 years was presented to us with a drop in reading vision in both eyes of 2 months duration. His best-corrected visual acuity was 6/24, N36 in both eyes. Fundus findings revealed moderate non-proliferative diabetic retinopathy with bilateral diffuse macular oedema.
Kavitha, Rao +3 more
openaire +2 more sources
Widening use of dexamethasone implant for the treatment of macular edema [PDF]
, 2017 Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T. +9 more
core +2 more sources